These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 24734891)

  • 1. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart.
    Tamborlane WV; Renard E; Wadwa RP; Blevins T; Jacober SJ; Liu R; D'Souza DN; Rees TM
    J Diabetes; 2015 Mar; 7(2):270-8. PubMed ID: 24734891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
    Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
    Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial.
    van Bon AC; Bode BW; Sert-Langeron C; DeVries JH; Charpentier G
    Diabetes Technol Ther; 2011 Jun; 13(6):607-14. PubMed ID: 21457066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes.
    Bartolo PD; Pellicano F; Scaramuzza A; Sardu C; Casetti T; Bosi E; Miselli V; Brandolini S; Fabbri T; Meandri P; Cannatà F
    Diabetes Technol Ther; 2008 Dec; 10(6):495-8. PubMed ID: 19049379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine-SORELLA 1 Study.
    Garg SK; Wernicke-Panten K; Rojeski M; Pierre S; Kirchhein Y; Jedynasty K
    Diabetes Technol Ther; 2017 Sep; 19(9):516-526. PubMed ID: 28722480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of insulins glulisine and aspart on postprandial glycemia after a high-glycemic index meal in children with type 1 diabetes.
    Dzygalo K; Szypowska A
    Eur J Endocrinol; 2014 Apr; 170(4):539-45. PubMed ID: 24412929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postprandial Glucose Excursions with Ultra-Rapid Insulin Analogs in Hybrid Closed-Loop Therapy for Adults with Type 1 Diabetes.
    Haliloglu B; Boughton CK; Lakshman R; Ware J; Nwokolo M; Thabit H; Mader JK; Bally L; Leelarathna L; Wilinska ME; Allen JM; Hartnell S; Evans ML; Hovorka R
    Diabetes Technol Ther; 2024 Jul; 26(7):449-456. PubMed ID: 38315506
    [No Abstract]   [Full Text] [Related]  

  • 9. Insulin Lispro with Continuous Subcutaneous Insulin Infusion is Safe and Effective in Patients with Type 2 Diabetes: A Randomized Crossover Trial of Insulin Lispro Versus Insulin Aspart.
    Thrasher J; Bhargava A; Rees TM; Wang T; Guzman CB; Glass LC
    Endocr Pract; 2015 Mar; 21(3):247-57. PubMed ID: 25370322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes.
    Garg SK; Buse JB; Skyler JS; Vaughn DE; Muchmore DB
    Diabetes Obes Metab; 2014 Nov; 16(11):1065-9. PubMed ID: 24840317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 2-way cross-over, open-labeled trial to compare efficacy and safety of insulin Aspart and Novolin R delivered with CSII in 21 Chinese diabetic patients.
    Bi YF; Zhao LB; Li XY; Wang WQ; Sun SY; Chen YH; Hong J; Su TW; Liu JM; Ning G
    Chin Med J (Engl); 2007 Oct; 120(19):1700-3. PubMed ID: 17935674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial.
    Mathieu C; Bode BW; Franek E; Philis-Tsimikas A; Rose L; Graungaard T; Birk Østerskov A; Russell-Jones D
    Diabetes Obes Metab; 2018 May; 20(5):1148-1155. PubMed ID: 29316130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fields of application of continuous subcutaneous insulin infusion in the treatment of diabetes and implications in the use of rapid-acting insulin analogues.
    Pitocco D; Rizzi A; Scavone G; Tanese L; Zaccardi F; Manto A; Ghirlanda G
    Minerva Endocrinol; 2013 Sep; 38(3):321-8. PubMed ID: 24126552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
    Bode BW
    Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Insulin Pump Therapy and Multiple Daily Injections Insulin Regimen in Patients with Type 1 Diabetes During Ramadan Fasting.
    Alamoudi R; Alsubaiee M; Alqarni A; Saleh Y; Aljaser S; Salam A; Eledrisi M
    Diabetes Technol Ther; 2017 Jun; 19(6):349-354. PubMed ID: 28296467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
    Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
    Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of prandial premixed therapy using insulin lispro mix 50/50 3 times daily compared with progressive titration of insulin lispro mix 75/25 or biphasic insulin aspart 70/30 twice daily in patients with type 2 diabetes mellitus: a randomized, 16-week, open-label study.
    Farcasiu E; Ivanyi T; Mozejko-Pastewka B; Birkus Z; Csog J; Kowalska I; Coetzer TF; Bulgurlu S; Schinzel B; Kiljanski J
    Clin Ther; 2011 Nov; 33(11):1682-93. PubMed ID: 22036246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump.
    Thrasher J; Surks H; Nowotny I; Pierre S; Rotthaeuser B; Wernicke-Panten K; Garg S
    J Diabetes Sci Technol; 2018 May; 12(3):680-686. PubMed ID: 29359575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes.
    Weinzimer SA; Ternand C; Howard C; Chang CT; Becker DJ; Laffel LM;
    Diabetes Care; 2008 Feb; 31(2):210-5. PubMed ID: 17989308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between preprandial vs. postprandial insulin aspart in patients with type 1 diabetes on insulin pump and real-time continuous glucose monitoring.
    Thuillier P; Sonnet E; Alavi Z; Roudaut N; Nowak E; Dion A; Kerlan V
    Diabetes Metab Res Rev; 2018 Sep; 34(6):e3019. PubMed ID: 29749032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.